By loading a chelation drug into a nano-sized homing device, researchers at Clemson University have reversed in an animal model the deadliest effects of chronic kidney disease, which kills more people in the United States each year than breast or prostate cancer.
When kidneys stop working properly, calcium builds up in artery tissue, leading to heart disease. Although nearly half a million Americans receive kidney dialysis, heart disease is the leading cause of death for people with chronic kidney disease.
“The findings are very exciting scientifically, but also for the thousands of patients who could potentially benefit from this technology one day,” said Naren Vyavahare, the Hunter Endowed Chair and professor of bioengineering at Clemson and the principal investigator of the research.
Chelation, a method of removing metals such as iron and lead from the body, has been used experimentally for some people with heart disease. The therapy is not approved by the Food and Drug Administration, but the National Institutes of Health has sponsored two large-scale, multi-center studies using ethylene diamine tetra-acetic acid, or EDTA, as chelation therapy for people with heart disease.
In clinical studies, EDTA is included in an infusion that circulates through the body; it’s systemic and non-specific. This method of chelation has shown good results in improving heart function, especially in diabetic patients, Vyavahare said. But EDTA infusion therapy is arduous (it requires 40 infusions over a period of a year), and it can cause side effects, including a depletion of calcium from the blood and from bone.
In 2014, Vyavahare’s team proved a targeted approach is effective. In animals without kidney disease, they loaded nanoparticles with EDTA and special antibodies that recognize and latch onto damaged elastin to deliver the therapy directly to arterial sites damaged by calcification.
Now, in a paper published Feb. 22, 2019, in Scientific Reports, a Nature publication, Vyavahare’s team describes how they developed an animal model that mimics a human’s chronic kidney disease. Animals were treated either with EDTA infusions, like in the NIH human trials, or with EDTA enclosed in a nanoparticle coupled with an antibody that seeks out damaged elastin. In animals that received the targeted therapy, calcium buildup was destroyed, without causing side effects, better than with EDTA infusions alone. Moreover, the calcification did not come back up to four weeks after the last injection, even though other signs of chronic kidney disease were present.
“Dr. Vyavahare’s work is extremely important for those of us who believe that calcium is not just a passive indicator of coronary disease, but also an active participant,” said Gervasio Lamas, chairman of medicine and chief of cardiology at Mount Sinai Medical Center in Miami Beach, Florida. Lamas, principal investigator of the NIH-funded Trial to Assess Chelation Therapy 2, was not involved in the Clemson study.
“The potential with a targeted drug is enormous, and the methodology for targeting that Dr. Vyavahare has developed is unique,” Lamas said.
Vyavahare and his co-authors wrote that in a previous study they showed that polyphenols, when delivered with nanoparticles, “regenerate degraded aortic elastin. Thus, there is an exciting opportunity of dual nanoparticle therapy to first remove calcium deposits using EDTA and then restore medial elastin layers with (polyphenols).”
Vyavahare has been studying elastin degradation and damages caused by calcification for nearly 20 years. He’s director of the NIH-funded South Carolina Center of Biomaterials for Tissue Regeneration.
The nanoparticle delivery technology has been licensed by Elastrin Therapeutics, a startup company Vyavahare helped found. He serves as chief science officer of the company.
“With recent funding we received from NIH to carry out more studies on understanding how reversal of calcification works, and Elastrin Therapeutics Inc. licensing this technology from Clemson University, we believe we would be able to translate this approach for use in clinical trials within the next few years,” Vyavahare said.
The Latest on: Chronic kidney disease
via Google News
The Latest on: Chronic kidney disease
- ‘I think he’d be very happy with what we’re doing,’ says mother of Niagara Falls teen who died 10 years ago of chronic kidney diseaseon December 5, 2021 at 10:55 am
The foundation started in 2012 following the 2011 death of David MacKinnon, an 18-year-old from Niagara Falls who lost his battle with chronic kidney disease and renal failure. Started by mother ...
- Immunotherapies, new gut peptides show promise for cardiometabolic diseaseson December 5, 2021 at 5:08 am
Emerging data suggest immunotherapies and novel peptides that target gut inflammation could serve as complementary agents to available diabetes drugs to more effectively target cardiometabolic ...
- Global Chronic Kidney Disease (CKD) Drugs Market Research Report 2021 - Impact of COVID-19 on the Marketon December 3, 2021 at 4:02 am
Pages Report] Check for Discount on Global Chronic Kidney Disease (CKD) Drugs Market Research Report 2021 - Impact of COVID-19 on the Market report by Maia Research. Chronic kidney disease (CKD) means ...
- A Better Test for Kidney Diseaseon December 1, 2021 at 12:30 pm
Researchers found a way to estimate kidney function that could help reduce racial bias in classifying chronic kidney disease.
- Rejuvenate Kidney Transplant Solutions announces new partnership to save lives through kidney transplantationon November 30, 2021 at 6:34 am
Rejuvenate Kidney Transplant Solutions announced today it has partnered with the Robert F. Kennedy Medical Plan to better manage chronic kidney disease (CKD) patients for its employee population.
- Chinook Therapeutics helps form China-based biotech venture to treat kidney diseaseon November 30, 2021 at 5:00 am
Chinook Therapeutics on Tuesday announced the formation of SanReno Therapeutics, which will advance therapies for kidney disease in China, Hong Kong, Macau, Taiwan and Singapore.
- Global Chronic Kidney Disease (CKD) Drug Market Research Report 2021 - Impact of COVID-19 on the Marketon November 29, 2021 at 4:00 pm
Pages Report] Check for Discount on Global Chronic Kidney Disease (CKD) Drug Market Research Report 2021 - Impact of COVID-19 on the Market report by Maia Research. Chronic kidney disease (CKD) is a ...
- Does My Dog Have Kidney Disease?on November 23, 2021 at 4:10 pm
Kidneys are vital organs (for you and your pup!) which is why you want to keep them healthy. But if your dog develops kidney disease, it’s important to know how it could affect him and what you can do ...
- What Is Chronic Kidney Disease? Doctors Explain the Causes and How It's Treatedon November 23, 2021 at 12:36 pm
Right now, 37 million Americans are living with chronic kidney disease (CKD), says the National Kidney Foundation (NKF). When you have this medical condition, it means your kidneys—the bean-shaped ...
- Vifor Pharma adds to chronic kidney disease lineup with pair of acquisitionson November 22, 2021 at 9:30 am
Nephrology products company Vifor Pharma is shelling out about $252 million combined up front to acquire Sanifit Therapeutics and Inositec, developers of drugs for a blood vessel complication ...
via Bing News